Sudhir Sahasrabudhe
Directeur/Bestuurslid bij Utah State University Foundation
Profiel
Sudhir Sahasrabudhe is currently an Associate Member at Massachusetts Institute of Technology and a Trustee at Utah State University Foundation.
He previously worked as Acting CEO & Chief Scientific Officer at Prolexys Pharmaceuticals, Inc., Senior Director-Biotechnology at Aventis Pharmaceuticals, Inc., and Executive Vice President-Research & Development at Myriad Genetics, Inc. Dr. Sahasrabudhe received his undergraduate and graduate degrees from the University of Baroda and his doctorate in 1987 from the same institution.
Actieve functies van Sudhir Sahasrabudhe
Bedrijven | Functie | Begin |
---|---|---|
Utah State University Foundation | Directeur/Bestuurslid | - |
Massachusetts Institute of Technology | Corporate Officer/Principal | - |
Eerdere bekende functies van Sudhir Sahasrabudhe
Bedrijven | Functie | Einde |
---|---|---|
MYRIAD GENETICS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Hoofd Techniek/Wetenschap/O&O | - |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Algemeen Directeur | - |
Opleiding van Sudhir Sahasrabudhe
University of Baroda | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
MYRIAD GENETICS, INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Utah State University Foundation | |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |